ClinicalTrials.Veeva

Menu

Pharmacogenomic Modulators of Impaired Exercise Adaptation in Statin Users

University of Kansas logo

University of Kansas

Status

Active, not recruiting

Conditions

HMG-CoA Reductase Inhibitor Toxicity

Treatments

Other: Exercise

Study type

Interventional

Funder types

Other

Identifiers

NCT04636138
STUDY00145686

Details and patient eligibility

About

3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins) have beneficial effects (prevent stroke, heart attack) but also some bad ones (block some good effects of exercise). Individuals have genetic variations in proteins that metabolize/transport statins. The investigators hypothesize that these variations modulate the relationship between statin use and lack of benefit from exercise. The investigators will test this by having statin-users do supervised exercise for 6 weeks, measuring the cardiorespiratory fitness before/after and correlating this to genetic variations present in the participant.

Enrollment

5 patients

Sex

All

Ages

35 to 65 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

  • English-speaking
  • Adults (aged 35-65 years)
  • Overweight or obese (body-mass index [BMI] 25-43)
  • Currently taking high-dose atorvastatin (40-80mg once daily) for primary prevention of cardiovascular disease and/or stroke
  • Sedentary (<30 minutes of structured exercise weekly)
  • Willing to participate in supervised exercise three times weekly
  • Willing to not make intentional changes to their diet during the study period.

Exclusion criteria

  • Tobacco smokers
  • Pregnant or breastfeeding
  • Use other medications that affect lipid metabolism (e.g. fibric acid, fish oil)
  • Markedly functional debilitated and unable to exert 4 metabolic equivalents (METs) of energy (e.g. unable to climb a flight of stairs without stopping), or who have
  • Been advised by a physician to avoid exercise due to comorbid serious cardiovascular disease
  • Uncontrolled diabetes (A1c > 8)
  • Uncontrolled thyroid disease
  • HIV/AIDS
  • Cancer
  • History of myocardial infarction or stroke
  • History of statin-induced myopathy.

Trial design

Primary purpose

Basic Science

Allocation

N/A

Interventional model

Single Group Assignment

Masking

None (Open label)

5 participants in 1 patient group

Single arm
Experimental group
Treatment:
Other: Exercise

Trial contacts and locations

1

Loading...

Central trial contact

Daniel J Parente, MD PhD

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems